These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37249666)

  • 1. Eyebrow alopecia associated with cladribine treatment for multiple sclerosis.
    Budimkic MS; Ivanovic J; Momcilovic N; Mesaros S; Drulovic J
    Neurol Sci; 2023 Oct; 44(10):3735-3736. PubMed ID: 37249666
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
    Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 4. Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    Deana C; Bagatto D; Battezzi A; Pecori D; Lorenzut S; Tuniz F
    J Neurol; 2022 Aug; 269(8):4557-4559. PubMed ID: 35352170
    [No Abstract]   [Full Text] [Related]  

  • 5. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
    Gummi R; Walsh RD; Ahmad B
    Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lichenoid rash: A new side effect of oral Cladribine.
    Aruta F; Iovino A; Costa C; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2020 Jun; 41():102023. PubMed ID: 32146431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alopecia associated with dimethyl fumarate treatment for multiple sclerosis.
    Abičić A; Adamec I; Habek M
    Wien Med Wochenschr; 2023 Sep; 173(11-12):287-289. PubMed ID: 36920580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
    J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
    Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
    Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of cladribine treatment in multiple sclerosis.
    Sipe JC; Romine JS; Koziol JA; McMillan R; Zyroff J; Beutler E
    Mult Scler; 1996 Jul; 1(6):343-7. PubMed ID: 9345414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.
    Cellerino M; Bonavita S; Ferrero M; Inglese M; Boffa G
    J Neurol Sci; 2020 Nov; 418():117156. PubMed ID: 33010653
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
    Hohlfeld R
    Nat Rev Neurol; 2011 Jul; 7(8):425-7. PubMed ID: 21750524
    [No Abstract]   [Full Text] [Related]  

  • 15. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 16. Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years.
    Disanto G; Moccia M; Sacco R; Spiezia AL; Carotenuto A; Brescia Morra V; Gobbi C; Zecca C
    Mult Scler Relat Disord; 2022 Feb; 58():103490. PubMed ID: 35007823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
    Meuth SG; Bayas A; Kallmann B; Linker R; Rieckmann P; Wattjes MP; Mäurer M; Kleinschnitz C
    Expert Opin Pharmacother; 2022 Sep; 23(13):1503-1510. PubMed ID: 35930260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.